fluoxetine has been researched along with olanzapine-fluoxetine combination in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (23.53) | 29.6817 |
| 2010's | 24 (70.59) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, MC | 1 |
| Briggs, SD; Case, M; Corya, SA; Sanger, TM; Shelton, RC; Tollefson, GD; Van Campen, LE; Williamson, DJ | 1 |
| Ladner, ME; Reeves, RR | 1 |
| Deeks, ED; Keating, GM | 2 |
| Azorin, JM; Kaladjian, A | 1 |
| Diaz, B; Fumero, I; Jamal, HH; Mattei, MA; Sutton, VK; Tamayo, JM; Tohen, M; Vieta, E; Zarate, CA | 1 |
| Cruz, N; Goikolea, JM; Sanchez-Moreno, J; Torres, F; Valentí, M; Vieta, E | 1 |
| Adams, DH; Fijal, B; Heinloth, AN; Houston, JP | 1 |
| Adams, DH; Breier, A; Farmen, M; Fijal, B; Houston, JP; Perlis, RH; Sutton, VK | 1 |
| Bobo, WV; Shelton, RC | 1 |
| Bishop, JR; Dharia, S; Ellingrod, VL; Fijal, B; Hoffmann, VP; Houston, J; Jacobson, JG | 1 |
| Case, M; Degenhardt, EK; Jamal, HH; Tormey, S | 1 |
| Citrome, L | 2 |
| Aris, V; Fijal, BA; Heinloth, AN; Houston, JP; Lau, K; Liu, W; Perlis, RH | 1 |
| Baker, RA; Forbes, RA; Jing, Y; Oster, G; Papakostas, GI; Taneja, C | 1 |
| Abelaira, HM; Agostinho, FR; Luciano, TF; Quevedo, J; Réus, GZ; Ribeiro, KF; Souza, CT; Vitto, MF | 1 |
| Galvao, TF; Pereira, MG; Silva, MT; Zimmermann, IR | 1 |
| Downar, J; Giacobbe, P; Kennedy, SH; Konarski, JZ; McIntyre, RS; Rizvi, SJ; Salomons, TV | 1 |
| Cha, DS; Kim, RD; Mansur, RB; McIntyre, RS | 1 |
| Bhadane, RP; Bonde, SL; Gaikwad, A; Gavali, SR; Katale, DU; Narendiran, AS | 1 |
| Brunner, E; Landry, J; Osuntokun, O; Thase, ME; Tohen, M | 1 |
| Cristancho, MA; Thase, ME | 1 |
| Gu, S; Guo, J; Luo, H; Qu, W; Tang, Q | 1 |
| McElroy, SL | 1 |
| Alarcon, RD; Biernacka, JM; Bobo, WV; Choi, DS; Frye, MA; Kung, S; Moore, KM; Prieto, ML; Tye, SJ; Veldic, M | 1 |
| Calabrese, JR; Citrome, L; Dell'Osso, B; Frye, MA; Ketter, TA; Miller, S | 1 |
| DelBello, MP; Detke, HC; Landry, J; Usher, RW | 1 |
| Baldessarini, RJ; Holtzman, JN; Tondo, L; Vázquez, GH | 1 |
| Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L | 1 |
| Abuzzahab, FS; Adson, DE; Lee, JT; Pardo, JV; Rittberg, B; Schwindt, G; Sheikh, SA | 1 |
| Diler, R; Machado, T; Patel, J; Patel, R; Patel, RS; Veluri, N | 1 |
14 review(s) available for fluoxetine and olanzapine-fluoxetine combination
| Article | Year |
|---|---|
Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression.
Topics: Acute Disease; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Fluoxetine; Humans; Quality of Life | 2008 |
Spotlight on olanzapine/fluoxetine in acute bipolar depression.
Topics: Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Drug Combinations; Fluoxetine; Humans | 2008 |
An update on the treatment of bipolar depression.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Administration Schedule; Drug Combinations; Fluoxetine; Humans; Meta-Analysis as Topic; Quetiapine Fumarate; Randomized Controlled Trials as Topic | 2009 |
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Combinations; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Placebos; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.
Topics: Adult; Age Factors; Antidepressive Agents; Benzodiazepines; Depression; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Fluoxetine; Humans; Kidney Diseases; Liver Diseases; Olanzapine; Randomized Controlled Trials as Topic | 2010 |
Olanzapine-fluoxetine combination for the treatment of bipolar depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Combinations; Fluoxetine; Humans; Quetiapine Fumarate | 2011 |
Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Combinations; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
A review of FDA-approved treatment options in bipolar depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzhydryl Compounds; Benzodiazepines; Bipolar Disorder; Central Nervous System Stimulants; Depressive Disorder; Dibenzothiazepines; Drug Approval; Drug Combinations; Excitatory Amino Acid Antagonists; Fluoxetine; Humans; Isoindoles; Ketamine; Lamotrigine; Lurasidone Hydrochloride; Modafinil; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Thiazoles; Triazines; United States; United States Food and Drug Administration | 2013 |
Drug safety evaluation of olanzapine/fluoxetine combination.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder, Major; Drug Combinations; Fluoxetine; Humans; Treatment Outcome | 2014 |
Treatment of bipolar depression: making sensible decisions.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder, Major; Dibenzothiazepines; Drug Combinations; Drug Therapy, Combination; Fluoxetine; Humans; Isoindoles; Lithium Compounds; Lurasidone Hydrochloride; Quetiapine Fumarate; Thiazoles; Valproic Acid | 2014 |
Current landscape, unmet needs, and future directions for treatment of bipolar depression.
Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Combinations; Fluoxetine; Forecasting; Health Services Needs and Demand; Humans; Isoindoles; Lamotrigine; Lurasidone Hydrochloride; Psychotherapy; Quetiapine Fumarate; Thiazoles; Triazines | 2014 |
Balancing benefits and harms of treatments for acute bipolar depression.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Combinations; Fluoxetine; Humans; Isoindoles; Lamotrigine; Lurasidone Hydrochloride; Multicenter Studies as Topic; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Thiazoles; Triazines; Weight Gain | 2014 |
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Citalopram; Depression; Depressive Disorder, Major; Drug Combinations; Fluoxetine; Humans; Inositol; Lamotrigine; Lithium; Triazines; Vitamin B Complex | 2016 |
Second-Generation Antipsychotics in Management of Acute Pediatric Bipolar Depression: A Systematic Review and Meta-analysis.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Brief Psychiatric Rating Scale; Child; Drug Combinations; Fluoxetine; Humans; Lurasidone Hydrochloride; Pediatrics; Psychopharmacology; Quetiapine Fumarate | 2021 |
9 trial(s) available for fluoxetine and olanzapine-fluoxetine combination
| Article | Year |
|---|---|
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Nortriptyline; Olanzapine; Pilot Projects; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico.
Topics: Adult; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Drug Combinations; Female; Fluoxetine; Hispanic or Latino; Humans; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Puerto Rico; Remission Induction; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Fluoxetine; Genome-Wide Association Study; Humans; Hyperprolactinemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Prolactin; Receptors, Dopamine D2; White People; Young Adult | 2010 |
Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Benzodiazepines; Bipolar Disorder; Dopamine beta-Hydroxylase; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Fluoxetine; Genetic Association Studies; Genotype; Humans; Lamotrigine; Male; Olanzapine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptor, Melanocortin, Type 2; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Glucocorticoid; Receptors, Histamine H1; Treatment Outcome; Triazines | 2010 |
Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis.
Topics: Antidepressive Agents, Second-Generation; Benzodiazepines; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Combinations; Fluoxetine; Genetic Association Studies; Genotype; Humans; Linkage Disequilibrium; Norepinephrine Plasma Membrane Transport Proteins; Olanzapine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptor, Melanocortin, Type 3; Selective Serotonin Reuptake Inhibitors; Tryptophan Hydroxylase | 2012 |
Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC-MS/MS: its pharmacokinetic application.
Topics: Adult; Benzodiazepines; Calibration; Chromatography, Liquid; Cross-Over Studies; Drug Combinations; Fluoxetine; Humans; Male; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Therapeutic Equivalency | 2014 |
Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Combinations; Female; Fluoxetine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Psychiatric Status Rating Scales; Secondary Prevention; Suicide; Time Factors; Treatment Outcome; Weight Gain | 2014 |
Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period.
Topics: Adult; Benzodiazepines; Depressive Disorder, Major; Drug Administration Schedule; Drug Combinations; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Quality of Life; Sleep Wake Disorders; Somatoform Disorders; Thiophenes | 2014 |
Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Child; Double-Blind Method; Drug Combinations; Female; Fluoxetine; Humans; Male; Psychiatric Status Rating Scales; Severity of Illness Index; Suicide, Attempted; Treatment Outcome; United States | 2015 |
11 other study(ies) available for fluoxetine and olanzapine-fluoxetine combination
| Article | Year |
|---|---|
Olanzapine/Fluoxetine (Symbyax) for bipolar depression.
Topics: Adult; Benzodiazepines; Bipolar Disorder; Drug Combinations; Fluoxetine; Humans; Olanzapine; Selective Serotonin Reuptake Inhibitors | 2004 |
Questions & answers. What is Symbyax, the new drug being marketed for the treatment of bipolar depression.
Topics: Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Drug Combinations; Fluoxetine; Humans | 2004 |
Does olanzapine-fluoxetine combination increase the risk of mania in poorly compliant bipolar depressed patients?
Topics: Adult; Benzodiazepines; Bipolar Disorder; Drug Combinations; Female; Fluoxetine; Humans; Patient Compliance; Risk Factors | 2005 |
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Drug Combinations; Female; Fluoxetine; Gene Frequency; Genome-Wide Association Study; Genotype; Humans; Meta-Analysis as Topic; Middle Aged; Olanzapine; Pharmacogenetics; Polymorphism, Single Nucleotide; Prolactin; Protein Serine-Threonine Kinases; Psychotic Disorders; Receptors, Dopamine D2; Sex Characteristics | 2011 |
Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression.
Topics: Benzodiazepines; Controlled Clinical Trials as Topic; Depression; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Sensitivity and Specificity; Time Factors; Weight Gain | 2011 |
Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Depressive Disorder, Major; Dibenzothiazepines; Drug Combinations; Drug Costs; Drug Resistance; Fluoxetine; Health Care Costs; Humans; Piperazines; Quetiapine Fumarate; Quinolones | 2012 |
The administration of olanzapine and fluoxetine has synergistic effects on intracellular survival pathways in the rat brain.
Topics: Animals; bcl-Associated Death Protein; Benzodiazepines; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Fluoxetine; Male; Neuroprotective Agents; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Signal Transduction | 2012 |
Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation.
Topics: Adult; Affect; Antidepressive Agents; Behavioral Symptoms; Benzodiazepines; Depressive Disorder, Major; Drug Combinations; Emotions; Female; Fluoxetine; Humans; Magnetic Resonance Imaging; Male; Middle Aged | 2013 |
Pros and cons of approved therapies for bipolar depression and ongoing unmet needs.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Combinations; Fluoxetine; Humans; Isoindoles; Lurasidone Hydrochloride; Quetiapine Fumarate; Thiazoles | 2014 |
Efficacy and tolerability of treatments for bipolar depression.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Combinations; Drug Therapy, Combination; Fluoxetine; Humans; Lurasidone Hydrochloride; Quetiapine Fumarate; Randomized Controlled Trials as Topic | 2015 |
A preliminary study of resting brain metabolism in treatment-resistant depression before and after treatment with olanzapine-fluoxetine combination.
Topics: Adult; Amygdala; Benzodiazepines; Brain; Depressive Disorder, Treatment-Resistant; Drug Combinations; Female; Fluoxetine; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Positron-Emission Tomography; Prefrontal Cortex; Severity of Illness Index | 2020 |